This bibliography shows a clinician with two distinct publication phases: an early-to-mid career period (1998–2016) dominated by pediatrics—especially pediatric hematology/oncology case series and complications, pediatric metabolic/obesity–NAFLD vascular risk markers (carotid IMT, hepcidin/iron metabolism), and pragmatic inflammatory indices (NLR, RDW) applied to common pediatric diagnoses. A later period (roughly 2013 onward, accelerating after 2018) shifts toward radiation oncology, with repeated work on head-and-neck radiotherapy (glottic/nasopharyngeal), re-irradiation and stereotactic techniques (CyberKnife/FSRT), and treatment-planning/targeting questions (VMAT/IMRT/tomotherapy, carotid-sparing). Authorship patterns include substantial first-author output in the pediatric/metabolic and early oncology papers, and increasing last-author roles in later years, consistent with supervising roles in single-center experiences and multicenter Turkish Radiation Oncology Society (TROD) group studies. The most-cited items cluster in 2004–2014 and are largely pediatric biomarker/association studies (vitamin D–ADHD; NLR/CRP-MPV in pneumonia; cIMT in obese children with NAFLD), suggesting their widest recognition comes from pediatric clinical epidemiology rather than the later radiotherapy portfolio.
Primary niche
Radiation oncology focused on head-and-neck radiotherapy planning and salvage/re-irradiation (carotid-sparing IMRT/VMAT; nasopharyngeal and early glottic cancer)
Secondary:
Pediatric clinical epidemiology/biomarkers in obesity–NAFLD vascular risk and inflammatory indices (cIMT, hepcidin/iron metabolism, NLR/RDW)
Career arc
Began (1998–2006) with cardiology/pericardial effusion and rhythm/hemodynamics papers, moved into pediatrics—especially hematology/oncology complications and metabolic/obesity vascular markers (2005–2016), then pivoted to radiation oncology with a sustained head-and-neck and neuro-oncology radiotherapy planning/salvage portfolio and multicenter TROD studies (2013–2025).
Authorship signal
group_leader
Reach:
mixed
Evidence quality
rich
•
concentrated